Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

FGF18 controls hair growth rest phase.

This opinion from the EFSA Panel concludes that the health claim regarding spermidine prolonging the anagen phase of the hair cycle does not meet regulatory criteria as it is related to disease treatment.

In this study, researchers analyzed dermal papilla cells from cashmere goats and identified 3,857 differentially expressed genes associated with hair growth phases, follicle types, and sex, providing a foundational resource for future efforts to improve cashmere quality and yield.

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

Escin helps keep hair follicles in the growth phase longer.

This study found that 3D imaging may serve as a promising tool for objectively evaluating facial vitiligo repigmentation after treatment with upadacitinib.

This study reported that male military personnel with pneumonia experienced accelerated hair transition to the telogen phase, particularly among smokers and those with androgenic alopecia, indicating potential areas for targeted interventions.

This study found that a novel topical dutasteride lotion, FOL100, demonstrated excellent safety, tolerability, and usability with promising signs of clinical benefit for mild-to-moderate male pattern baldness.

This study found that combining photobiomodulation therapy with minoxidil significantly improved hair quality and reduced telogen-phase hair counts more effectively than minoxidil alone in women with female pattern hair loss over a shorter 12.5-week period.

This study demonstrates that pea sprout extract promotes hair growth by activating specific signaling pathways and providing antioxidant and anti-inflammatory effects, suggesting its potential as a natural alopecia treatment.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

In AGA animal models, this study found that finasteride-loaded microspheres provided rapid and sustained dihydrotestosterone suppression, promoting hair regrowth through dual-phase drug release.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

Glycogen helps E. coli cells divide unevenly and organize their contents.

In this study, S. chamaejasme extract applied topically to mice enhanced hair growth dose-dependently by increasing hair follicle size and dermal thickness, while upregulating mRNA expression related to hair growth, suggesting its potential as a hair growth treatment.

The topical finasteride spray was safe and well-tolerated with stable effects.

In this study, oral spermidine supplementation was found to significantly prolong the hair follicle anagen phase and reduce hair loss, with effects persisting three months after treatment in healthy participants, suggesting potential therapeutic benefits for hair loss conditions.

This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This study found that 18-β-Glycyrrhetinic acid, a licorice component, stimulated human hair follicle cell proliferation, inhibited testosterone 5α-reductase, and suppressed TGF-β1, suggesting potential for treating androgenetic alopecia by promoting hair growth and prolonging the anagen phase.

This study observed that pilose antler extract promoted hair growth in mice with androgenetic alopecia by stimulating the hair follicle growth cycle via the SHH/GLI pathway activation and BMP/Smad pathway suppression.

In this study, injecting dermal sheath cup cells into affected areas of pattern hair loss improved hair thickness and patient-reported hair appearance in 62.9% of the participants, with better results in women, without serious side effects.